UK: The Medicines and Healthcare products Regulatory Agency (MHRA) is the first Western nation to approve the Pfizer-BioNTech vaccine for emergency use. Dr. June Raine, the executive director of the British regulator, assured the public that “no corners were cut” in the approval process. Her Majesty’s government has ordered 40-million doses, enough to vaccinate 20-million people. An initial 800,000 doses are expected to arrive in Britain next week. Each patient will receive two doses 21 days apart. The speed at which vaccinations will take place will depend on how quickly the shot can be manufactured at a plant in Belgium. The Pfizer vaccine must be stored at a temperature that’s colder than the North Pole. It is a RNA vaccine that has a bad reputation for triggering autoimmune reactions that causes the body to attack itself. Unfortunately, most of the people clamoring for the vaccine know nothing of this risk.China and Russia have already authorized emergency use of vaccines developed domestically. China is believed to have already vaccinated more than 1-million people. The US and the rest of Europe are scrambling to jump on the wagon despite the fact that COVID-19 has a 99.9% survival rate for people under 70 years old.
Britain’s MHRA placed an advertisement seeking a custom software tool to “process the expected high-volume Covid-19 Adverse Drug Reaction,” because a high rate of vaccine injury is expected. -GEG
Arguing that the benefits of the vaccine “far outweigh the risks” from expedited approval, British regulator MHRA – Medicines and Healthcare products Regulatory Agency – has become the first in the West to approve the Pfizer-BioNTech vaccine for emergency use, a landmark decision that has once again lifted the market’s mood as the never-ending procession of vaccine news continues.
Dr. June Raine, the executive director of the British regulator, assured the public that “no corners were cut” in the approval process, which was carried out under EU law (which the UK is obliged to honor until Jan. 1). Now, the UK, which has been testing large-scale delivery systems for the vaccine (which has very cumbersome temperature requirements (it must be stored at a temperature that’s colder than the north pole) will be the first in the West to test its logistical prowess as regulators in the US and Brussels scramble to catch up.
Distribution of the vaccine in the UK will start on Monday.